EDEN Bioscience Receives Delisting Warning Letter From Nasdaq

Published: Dec 13, 2006

BOTHELL, WA -- (MARKET WIRE) -- December 12, 2006 -- Eden Bioscience Corporation (NASDAQ: EDEN) today announced that on December 11, 2006 it received a Nasdaq Staff Deficiency Letter from the Nasdaq Stock Market notifying it that the closing price per share for the Company's common stock was below the $1.00 minimum bid price requirement for 30 consecutive trading days and that, as a result, the Company no longer meets The Nasdaq Capital Market's minimum bid price requirement for continued listing set forth in Marketplace Rule 4310(c)(4). Nasdaq has provided the Company with 180 calendar days, or until June 11, 2007, to regain compliance.

Back to news